#3-98E. Optimizing First-Line Treatments: PROs in Early Rheumatoid Arthritis (Lancet Rheumatol, 2026)

Is initiating treatment with biologic disease-modifying antirheumatic drugs essential for improving subjective symptoms in newly diagnosed rheumatoid arthritis? In this episode, we explore the 48-week patient-reported outcomes (PROs) from the NORD-STAR trial, which compared active conventional therapy against three biologic agents: certolizumab pegol, abatacept, and tocilizumab. The study demonstrated that all treatment groups experienced substantial improvements in pain, fatigue, and health-related quality of life over time. The key takeaway from this research is that early, aggressive disease control significantly improves PROs regardless of the specific therapy type utilized6.** However, when critically appraising these results, listeners should consider the open-label design of the trial, which may have introduced a favorable bias in subjective PRO assessments due to patient expectations for novel biologic treatments.** Nevertheless, this paper holds significant clinical value for practicing physicians, as it underscores that administering intensive conventional therapy can yield sufficient improvements in patient quality of life, potentially circumventing the immediate need for costly biologics and thus directly informing everyday first-line treatment decisions.

Citation: Lampa J, et al. Certolizumab pegol, abatacept, tocilizumab or active conventional therapy in early rheumatoid arthritis: 48-week patient-reported outcomes from the NORD-STAR trial. Lancet Rheumatol. 2026.

Disclaimer: This audio summary is based on personal interpretation and does not guarantee the exact content of the original paper. Please refer to the original article for details.